CRISM Therapeutics Corporation
CRTX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £837 | £1,596 | £16,819 | £31,837 |
| - Cash | £1,282 | £3,439 | £2,896 | £4,933 |
| + Debt | £0 | £889 | £0 | £0 |
| Enterprise Value | -£445 | -£955 | £13,923 | £26,904 |
| Revenue | £25 | £57 | £0 | £0 |
| % Growth | -56.4% | – | – | – |
| Gross Profit | £21 | £17 | £0 | £0 |
| % Margin | 84% | 28.9% | – | – |
| EBITDA | -£566 | -£2,259 | -£1,806 | -£1,300 |
| % Margin | -2,264% | -3,937.9% | – | – |
| Net Income | -£607 | -£9,647 | -£2,446 | -£1,542 |
| % Margin | -2,428% | -16,816.6% | – | – |
| EPS Diluted | -0.1 | -0.27 | -0.28 | -0.18 |
| % Growth | 63% | 3.6% | -55.6% | – |
| Operating Cash Flow | -£933 | -£2,770 | -£2,726 | -£1,095 |
| Capital Expenditures | -£28 | £0 | -£265 | -£310 |
| Free Cash Flow | -£961 | -£2,770 | -£2,992 | -£1,405 |